ArticleJundishapur journal of microbiology2015
In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey.
Article in Jundishapur journal of microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Vulvovaginal candidiasis among Yemeni women: prevalence of Candida species, biofilm formation rates, antifungal susceptibility patterns, and biofilm-associated genes ALS1 and HWP1.BMC microbiology · 2026Article
- Epidemiological and microbiological characterization of Candidozyma auris (Candida auris) isolates from a tertiary hospital in Cairo, Egypt: an 18-month study.Scientific reports · 2025Article
- Twenty-Year Course of Antifungal Resistance inJournal of fungi (Basel, Switzerland) · 2025Review
- Article
- The efficacy of luliconazole and caspofungin on planktonic and biofilm ofIranian journal of microbiology · 2025Article
- Distribution of fungal agents in the respiratory system of patients with underlying lung diseases; molecular identification and antifungal susceptibility profiles.Iranian journal of microbiology · 2024Article
- Snakes as sentinel of zoonotic yeasts and bio-indicators of environmental quality.Scientific reports · 2024Article
- Candidemia in Brazilian neonatal intensive care units: risk factors, epidemiology, and antifungal resistance.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Fungal diversity and drug susceptibility of the oral mycobiome of domestic dogs.Frontiers in veterinary science · 2023Article
- Biofilm Formation and Aspartyl Proteinase Activity and Their Association with Azole Resistance AmongInfection and drug resistance · 2023Article
- Candiduria-Study of Virulence Factors and Its Antifungal Susceptibility Pattern in Tertiary Care Hospital.Journal of laboratory physicians · 2021Article
- Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species.Scientific reports · 2020Article
- Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities.Scientific reports · 2020Article
- Antifungal Susceptibility and Biofilm Production ofInternational journal of microbiology · 2018Article
- Evaluation ofTurk pediatri arsivi · 2017Article
- The Frequency, Antifungal Susceptibility and Enzymatic Profiles ofJundishapur journal of microbiology · 2016Article
- Susceptibility pattern ofCurrent medical mycology · 2016Article
- Comparison of clinical pharmacology of voriconazole and posaconazole.Contemporary oncology (Poznan, Poland) · 2016Review
- Molecular identification andCurrent medical mycology · 2015Article
- Emergence of azole-resistantCurrent medical mycology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida albicans is the pathogenic species most commonly isolated from fungal infections. Management of these infections depends on the immune status of the host, severity of disease, and the choice of antifungal drug. In spite of the development of new antifungal drugs, epidemiological studies have shown that resistance to antifungal drugs in C. albicans strains is becoming a serious problem.
objectivesThe aim of this study was to evaluate the in vitro susceptibility of C. albicans isolates to ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, amphotericin B, caspofungin, and anidulafungin. MATERIALS AND
methodsA total of 201 C. albicans isolates were collected from clinical specimens. Antifungal susceptibility tests were performed using the Etest.
resultsAll the tested C. albicans isolates were found to be susceptible to amphotericin B and anidulafungin. Although none of the isolates showed resistance to caspofungin, 15% of the isolates were classified as showing intermediate resistance. The resistance rates of C. albicans isolates to ketoconazole, fluconazole, itraconazole, voriconazole and posaconazole were 32%, 34%, 21%, 14% and 14%, respectively.
conclusionsOur findings indicate that resistance of C. albicans strains to azoles is more common in Tokat, Turkey. Therefore, a strategy to control the inappropriate and widespread use of antifungal drugs is urgently needed. Fungal culturing and antifungal susceptibility testing will be useful in patient management as well as resistance surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.